There haven’t been any national guidelines developed for managing patients with stage 1 hypertension who don’t respond to lifestyle modification. This population represents an important guideline gap: most patients with stage 1 hypertension progress to stage 2 hypertension, which increases the risk for cardiovascular events. The AHA has published a scientific statement to fill the gap – if lifestyle modification fails to reduce blood pressure, consider pharmacotherapy.